We not only validated the efficacy of the identified BCL6 inhibitor WK369 as a monotherapy for ovarian cancer, but also provided a potential therapeutic option for the use of targeted agents in adjuvant chemotherapy. This evidence concerns the gene BCL6 and ovarian carcinoma.